TICKERNERD
Menu
HQYHQYHealthcare · Health Information Services

HQY Stock Forecast: HealthEquity, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$89
−1.98% on the day

The 15 Wall Street analysts covering HealthEquity, Inc. hold a median 12-month price target of $120 — +35.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 23 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$7.6B
Ticker Nerd rank
94 / 100
Median analyst target
$120
Analysts covering
15
Revenue$350.7M+7.6% y/y
Operating income$99.7M
Net income$65.6M
Free cash flow$120.4M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.3%
1M
−15.9%
YTD
−3.3%
1Y
−6.0%
From 52W high
−17.0%
From 52W low
+21.0%
$73
$107
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HQY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HealthEquity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
96
Volatility
91
Accruals
87
Quality
86
Revisions
75
Value
71
Momentum
66
Growth
54
Size
18

Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (54): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HQY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HQY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140Oct 25Jan 26Apr 26Jul 26HQYHigh $142Median $120Low $105

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $105Median $120High $142

The green dot is the last close — the median target sits +35.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Sept 2026BarclaysMaintainsOverweight$110 → $115
31 Aug 2026Deutsche BankMaintainsBuy$135 → $142
31 Aug 2026Deutsche BankMaintainsBuy—
28 Aug 2026BTIGReiteratesBuy$115
28 Aug 2026BTIGReiteratesBuy—
24 July 2026BTIGMaintainsBuy$110 → $115
24 July 2026BTIGMaintainsBuy—
3 June 2026RBC CapitalReiteratesOutperform$108
3 June 2026RBC CapitalReiteratesOutperform—
1 June 2026CitizensMaintainsMarket Outperform$110 → $111
1 June 2026CitizensMaintainsMarket Outperform—
29 May 2026RBC CapitalMaintainsOutperform$100 → $108
29 May 2026RBC CapitalMaintainsOutperform—
22 May 2026Barrington ResearchMaintainsOutperform—
9 Apr 2026BMO CapitalUpgradeOutperform—
19 Mar 2026Deutsche BankMaintainsBuy—
18 Mar 2026Barrington ResearchMaintainsOutperform—
18 Mar 2026JP MorganMaintainsOverweight—
18 Mar 2026RBC CapitalMaintainsOutperform—
18 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HQY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HQY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, HealthEquity, Inc. returned −6.0% against +17.3% for the S&P 500, dividends included.

HQY vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26HQYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HQY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.2%
Analysts raising
5
Analysts cutting
2
Fundamentals

HealthEquity, Inc. (HQY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.8×

Cheaper than 23% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
3.8×

Cheaper than 27% of US stocks

EV / EBITDA
16.2×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
7.6%

Higher than 46% of US stocks

Earnings growth (YoY)
9.7%

Higher than 48% of US stocks

Gross margin
73.5%

Higher than 86% of US stocks

Operating margin
28.4%

Higher than 86% of US stocks

Net margin
17.4%

Higher than 80% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 67% of US stocks

Return on assets
6.7%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HealthEquity, Inc. (HQY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HealthEquity, Inc. has a market value of $7.6B and an enterprise value of $8.3B.

  • Revenue in the twelve months to 31 July 2026: $1.4B. The latest quarter grew 7.6% year on year.

  • Net income over the same four quarters: $236.5M, a 17.4% net margin.

  • Diluted earnings per share, trailing twelve months: $2.77.

  • Free cash flow in the twelve months to 31 July 2026: $436.7M.

  • HealthEquity, Inc. spent $404.5M on share buybacks in the twelve months to 31 July 2026.

  • Shares outstanding: 82.9M.

  • Trailing P/E: 32.8×; forward P/E: 16.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • HealthEquity, Inc. employs 2,814 people — $484K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 23 Sept 2026

Data provided by Twelve Data

Peers

HQY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HQYHealthEquity, Inc.$7.6B
94
HNGEHinge Health, Inc.$7.1B
80
BTSGBrightSpring Health Services, Inc.$10.8B
89
DOCSDoximity, Inc.$4.9B
62
WAYWaystar Holding Corp.$4.7B
39
TEMTempus AI, Inc.$13.7B
24
HTFLHeartFlow, Inc.$4.1B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HealthEquity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HQY news & analysis

Here's Why HealthEquity (HQY) is a Strong Growth Stock

Zacks Investment Research · 24 Sept 2026positive

Zacks Investment Research highlights HealthEquity as a strong growth stock, referencing its Zacks Style Scores as a tool for identifying market-beating stocks. The piece positions HQY among stocks flagged for strong growth characteristics.

Why it matters — HQY watchers would care because the article signals that HealthEquity is being recognized by Zacks' screening methodology as a compelling growth stock for investors.

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

Zacks Investment Research · 4 Sept 2026neutral

Zacks Investment Research highlights that HealthEquity's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern. The report suggests reasons to hold the stock for now.

Why it matters — HQY watchers would care because the item outlines both the company's growth drivers (rising HSA assets and AI efficiencies) and its primary risk (cybersecurity), informing how they view the stock's prospects.

HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?

Zacks Investment Research · 2 Sept 2026positive

HealthEquity shares rose 15.7% over three months, a rally attributed to growing HSA scale, improved margins, and higher guidance. The article notes that key risks remain despite this momentum.

Why it matters — A HQY watcher would care because the reported gains signal strengthening HSA business fundamentals and enhanced forward guidance, while the flagged risks highlight what to watch next.

Here's Why HealthEquity (HQY) is a Strong Growth Stock

Zacks Investment Research · 2 Sept 2026positive

Zacks Investment Research published an article highlighting HealthEquity (HQY) as a strong growth stock, referencing its Zacks Style Scores feature from the Zacks Premium research service as a tool for identifying such stocks.

Why it matters — The article positions HQY favorably as a strong growth stock, which is relevant to investors tracking the company's growth profile.

Why HealthEquity Stock Sank This Week

The Motley Fool · 30 Aug 2026negative

HealthEquity reported significant fiscal Q2 sales and earnings beats, and issued a small increase to its full-year guidance while keeping its adjusted earnings-per-share forecast unchanged. Despite the strong results, the stock declined during the week.

Why it matters — A HQY watcher would care because the company beat expectations and raised guidance yet saw its shares fall, signaling investor disappointment over the unchanged adjusted EPS outlook.

FAQ

Frequently asked questions about HQY stock

What is the HQY stock price forecast for 2026-2027?

The 15 Wall Street analysts covering HealthEquity, Inc. have a median 12-month price target of $120, with estimates ranging from $105 to $142. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HQY stock a buy right now?

Of the 15 analysts covering HealthEquity, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HealthEquity, Inc. 94 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HQY?

As at 23 Sept 2026, HealthEquity, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).

Will HQY stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +35.4% from the last close, and Ticker Nerd's factor model ranks HealthEquity, Inc. 94 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HQY stock forecast for 2030?

No analyst covering HealthEquity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HQY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $142 over the next 12 months.

How has HQY stock performed over the past year?

HealthEquity, Inc. returned -6.0% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HealthEquity, Inc. do?

HealthEquity, Inc. is a healthcare-fintech and benefits administration company that provides technology-enabled platforms for managing tax-advantaged health accounts and related employee benefits.

What is the latest news on HQY?

The most recent item we track (Zacks Investment Research, 24 Sept 2026): "Here's Why HealthEquity (HQY) is a Strong Growth Stock". Zacks Investment Research highlights HealthEquity as a strong growth stock, referencing its Zacks Style Scores as a tool for identifying market-beating stocks. The piece positions HQY among stocks flagged for strong growth characteristics.

Company

About HealthEquity, Inc.

HealthEquity, Inc. is a healthcare-fintech and benefits administration company that provides technology-enabled platforms for managing tax-advantaged health accounts and related employee benefits. HealthEquity focuses on health savings accounts, flexible spending accounts, health reimbursement arrangements, COBRA continuation services, commuter benefits, and other consumer-directed benefit programs. Its services are designed to help consumers and employers organize healthcare spending, access account information, process payments, and manage eligible investments through digital tools and support services. The company works with employers, benefits advisors, health plans, and retirement providers to administer account-based benefit programs across the United States. HealthEquity plays a key role in the consumer-directed healthcare market by combining account administration, payment capabilities, and member support in a single platform.

CEO Mr. Scott R. Cutler J.D. · 2,814 employees · United States · https://www.healthequity.com